Medicare drug price rule may target under-the-skin Keytruda and Opdivo

Medicare drug price rule may target under-the-skin Keytruda and Opdivo

For 2029, a federal rule proposes closing a "loophole" that protects medicines transitioning from intravenous administration from price protection.

CMS Proposes Creating Permanent Framework for Medicare Drug Price Negotiations - The Thinking Conservative News

CMS proposed a permanent framework for its Medicare drug price negotiation program that will make the process for lowering costs more transparent. The post CMS Proposes Creating Permanent Framework for Medicare Drug Price Negotiations appeared first on The Thinking Conservative News.

CMS Proposes Creating Permanent Framework for Medicare Drug Price Negotiations

The U.S. Centers for Medicare and Medicaid Services (CMS) has proposed a permanent framework for its Medicare drug price negotiation program that it said will make the process for lowering costs more transparent. The agency said in a June 12 statement that the proposed rule also aimed at providing long-term certainty for drugmakers participating in the program. It stated that the proposed rule would establish policies for negotiating and renegot…

Medicare drug price rule may target under-the-skin cancer immunotherapies

For 2029, a federal rule proposes closing a "loophole" that protects medicines transitioning from intravenous administration from price protection.

Agencies issue proposed rule codifying Medicare Drug Price Negotiation Program

The Department of Health and Human Services and the Centers for Medicare & Medicaid Services released a proposed rule June 12 seeking to codify the Medicare Drug Price Negotiation Program in regulation. The proposal would largely codify existing guidance but also contains some new provisions and modifications, including a clarification regarding new formulations of drugs.

CMS seeks to close Medicare negotiation 'loophole'

CMS has proposed a policy change that clarifies its stance on how products are grouped together for Medicare negotiations. Under the Inflation Reduction Act, biologics become eligible for Medicare negotiations 11 years after their approval ...